Diabetic macular oedema (DME)

This site contains promotional content intended for Healthcare Professionals in Ireland and other relevant decision makers | Not a HCP? Visit our Public Site.
Adverse Event reporting can be found at the bottom of the page | Prescribing Information for the relevant medicine can be found adjacent to the below content and/or in the footer below.

Diabetic Macular Oedema (DME)

EYLEA 8mg (aflibercept 114.3 mg/ml) is indicated in adults for the treatment of neovascular (wet) age-related macular degeneration (nAMD) and visual impairment due to diabetic macular oedema (DME).

For those who want flexibity to optimise patient intervals to Q16 and beyond

Save sight

whilst minimising treatment burden

Flexibility to extend treatment

intervals as far as Q24

Suppress VEGF

with a safety profile comparable to EYLEA 2mg.

PHOTON

Eylea 8mg: The opportunity to extend intervals with confidence

Primary endpoint: mean change in BCVA from baseline to Week 48

With EYLEA 8mg, patients achieved lasting BCVA gains from baseline with as few as 5 injections in Year 1^*

EYLEA 8mg was non-inferior vs. EYLEA 2mg

^{* Includes 3 initial monthly doses.}

Week 48

Flexibility to extend treatment intervals for eligible DME patients

In PHOTON, ~9 out of 10 patients maintained 16-week treatment intervals from baseline through Week 48^*

^{* Patients completing Week 48: 2Q8 n=157; 8Q12 n=300; 8Q16 n=156.}

Week 96

Flexibility to extend treatment intervals for eligible patients across your DME clinic

In PHOTON, ~9 out of 10 patients achieved a last assigned dosing interval of ≥Q16 at Week 96^*

^{* Patients completing Week 96: 8Q12 n=256; 8Q16 n=139.}

Flexibility to extend treatment intervals beyond expectations

The first and only anti-VEGF for DME that allows for extension to treatment intervals of Q24 after reaching Q16^*

^{* Following 3 monthly loading doses, intervals can be extended to Q16, dependent on visual and/or anatomic outcomes, and subsequently to Q24 (e.g. with a T&E regimen) if visual and/or anatomic outcomes are stable. Consult the SmPC for full posology}
^{† Patients completing Week 96: 8Q12 n=256; 8Q16 n=139.}

Discover more about how you can meet the needs of your eligible nAMD patients with EYLEA 8mg

Dosing

Discover proactive dosing in nAMD and DME

Mechanism of Action (MoA)

Discover more about the MoA of EYLEA 8mg

Abbreviations

2Q8

^{, 2mg every 8 weeks;}^8Q12^{, 8mg every 12 weeks;}^8Q16^{, 8mg every 16 weeks;}^BCVA^{, best-corrected visual acuity;}^BMI^{, body mass index;}^CI^{, confidence interval;}^CRT^{, central retinal thickness;}^DME^{, diabetic macular oedema;}^DRM^{, dosing regimen modification;}^DRSS^{, diabetic retinopathy severity study;}^ETDRS^{, Early Treatment of Diabetic Retinopathy Study;}^FAS^{, full analysis set;}^ICE^{, intercurrent event;}^LS^{, least squares;}^MMRM^{, mixed model for repeated measurements;}^MoA^{, mechanism of action;}^nAMD^{, neovascular (wet) age-related macular degeneration;}^Q8^{, every 8 weeks;}^Q12^{, every 12 weeks;}^Q16^{, every 16 weeks;}^Q20^{, every 20 weeks;}^Q24^{, every 24 weeks;}^SAF^{, safety analysis set;}^SD^{, standard deviation;}^SmPC^{, Summary of Product Characteristics;}^T&E^{, treat and extend;}^VEGF^{, vascular endothelial growth factor.}

PP-EYL_8mg-IE-0153-1 | December 2025

References

1
EYLEA® 114.3 mg/mL Summary of Product Characteristics.
2
Do D. Aflibercept 8 mg for diabetic macular edema: 48-week results from the Phase 2/3 PHOTON trial. ARVO. 23–27 April 2023. Palo Alto, USA. Oral presentation.
3
Wykoff CC. Aflibercept 8 mg for diabetic macular edema: 96-week results from the Phase 2/3 PHOTON trial. EURETINA. 5–8 October 2023. Amsterdam, The Netherlands. Oral presentation.
4
Brown DM. Intravitreal aflibercept injection 8 mg for DME: 48-week results from the Phase 2/3 PHOTON trial. Retina Society. 2–5 November 2022. Pasadena, USA. Oral presentation.
5
ClinicalTrials.gov. NCT04429503. Available at: https://classic.clinicaltrials.gov/ct2/show/NCT04429503. Accessed: December 2025